BackGracell Biotechnologies Overview

Gracell Biotechnologies Common Stock

Track Gracell Biotechnologies's common stock ($320K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$324000.00
↑ 45.29% YoYΔ $101000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Gracell Biotechnologies Common Stock History

Loading

Gracell Biotechnologies vs. peers: Common Stock Comparison

Loading

Gracell Biotechnologies Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Gracell Biotechnologies (GRCL) FAQ

Gracell Biotechnologies (GRCL) currently reports a common stock of $320K as of September 2023. That compares with $220K in the prior-year period — up 45.3% year over year. Use the charts on this page to explore Gracell Biotechnologies's common stock history and peer comparisons.

Gracell Biotechnologies's common stock increased from $220K to $320K — a 45.3% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gracell Biotechnologies reported $320K in common stock as of September 2023. That compares with $220K in the prior-year period — up 45.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $320K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gracell Biotechnologies, and consider following GRCL for alerts when major investors trade the stock.

Gracell Biotechnologies is classified in the Healthcare sector. On common stock, it currently shows $320K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GRCL with unrelated industries.